/KZR
KZR Stock - Kezar Life Sciences, Inc.
Healthcare|BiotechnologyNASDAQ
$6.34+0.32%
+$0.02 (+0.32%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.91
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).39
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-5.4%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KZR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.28 – $6.40
TARGET (TP)$6.00
STOP LOSS$5.83
RISK/REWARD1:-0.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.51
52W High$6.95
52W Low$3.53
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $7.00M | N/A | N/A | N/A |
| Gross Profit | N/A | $7.00M | N/A | $-1,510,000 | $-1,544,000 |
| Gross Margin | N/A | 100.0% | N/A | N/A | N/A |
| Operating Income | $-90,605,000 | $-111,424,000 | $-71,162,000 | $-54,659,000 | $-43,008,000 |
| Net Income | $-83,736,000 | $-101,870,000 | $-68,239,000 | $-54,630,000 | $-41,742,000 |
| Net Margin | N/A | -1455.3% | N/A | N/A | N/A |
| EPS | $-1.15 | $-1.40 | $-1.01 | $-1.04 | $-0.95 |
Company Overview
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
2
100%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish2 Neutral/Bearish
Price Targets
$6
Average Target
↓ 13.2% Downside
Now
$4
Low
$6
Average
$7
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 17th 2025 | Jefferies | Downgrade | Hold | $7 |
| October 17th 2025 | William Blair | Downgrade | Market Perform | - |
| August 11th 2023 | Wells Fargo | Downgrade | Equal Weight | $4 |
| March 16th 2023 | William Blair | Downgrade | Market Perform | - |
Earnings History & Surprises
KZRBeat Rate
68%
Last 19 quarters
Avg Surprise
+5.3%
EPS vs Estimate
Beats / Misses
13/6
Last 12 quarters
Latest EPS
$-1.53
Q4 2025
EPS Surprise History
Q1 24
+10.3%
$-3.50vs$-3.90
Q2 24
+11.8%
$-3.00vs$-3.40
Q3 24
+12.5%
$-2.80vs$-3.20
Q4 24
+8.3%
$-2.78vs$-3.03
Q1 25
-2.2%
$-2.77vs$-2.71
Q2 25
+11.3%
$-2.27vs$-2.56
Q3 25
+13.0%
$-1.87vs$-2.15
Q4 25
+15.5%
$-1.53vs$-1.81
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-1.39 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-1.81 | $-1.53 | +15.5% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-2.15 | $-1.87 | +13.0% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-2.56 | $-2.27 | +11.3% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $-2.71 | $-2.77 | -2.2% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-3.03 | $-2.78 | +8.3% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-3.20 | $-2.80 | +12.5% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-3.40 | $-3.00 | +11.8% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-3.90 | $-3.50 | +10.3% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-3.60 | $-3.20 | +11.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-3.30 | $-3.40 | -3.0% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-2.80 | $-3.10 | -10.7% | ✗ MISS |
Q1 2023 | Mar 14, 2023 | $-2.40 | $-2.50 | -4.2% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-2.60 | $-2.50 | +3.8% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-2.70 | $-2.50 | +7.4% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-2.90 | $-2.60 | +10.3% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-2.90 | $-2.50 | +13.8% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-2.60 | $-2.80 | -7.7% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-2.60 | $-2.50 | +3.8% | ✓ BEAT |
Q2 2021 | May 12, 2021 | $-2.40 | $-2.50 | -4.2% | ✗ MISS |
Latest News
Kezar Life Sciences Q3 EPS $(1.53) Beats $(2.08) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:33 PM
Kezar Life Sciences Announces 70% Workforce Reduction As Part Of Strategic Restructuring Plan; Estimates $6M In Restructuring Costs; Expects To Recognize Costs In Q4 2025
📉 NegativeBenzinga•Nov 7, 2025, 09:24 PM
Kezar Life Sciences Announced Two Presentations From The Completed Phase 2A Portola Clinical Trial In Patients With Autoimmune Hepatitis At The Liver Meeting 2025 In Washington, DC
📈 PositiveBenzinga•Nov 7, 2025, 12:10 PM
Kezar Life Sciences Announces Two Presentations From Completed Phase 2a PORTOLA Clinical Trial In Patients With Autoimmune Hepatitis At 2025 AASLD
➖ NeutralBenzinga•Nov 7, 2025, 12:08 PM
Jefferies Downgrades Kezar Life Sciences to Hold, Lowers Price Target to $7
📉 NegativeBenzinga•Oct 17, 2025, 07:08 PM•Also:
William Blair Downgrades Kezar Life Sciences to Market Perform
📉 NegativeBenzinga•Oct 17, 2025, 02:22 PM
Wells Fargo Maintains Equal-Weight on Kezar Life Sciences, Lowers Price Target to $5
➖ NeutralBenzinga•Oct 17, 2025, 01:01 PM
Kezar Life Sciences Initiates Strategic Alternatives Review, Announces Workforce Restructuring And Rights Plan Extension After FDA Blocks Path Forward For Zetomipzomib In Autoimmune Hepatitis; Reports $90.2M Cash Balance
📉 NegativeBenzinga•Oct 16, 2025, 08:09 PM
Frequently Asked Questions about KZR
What is KZR's current stock price?
Kezar Life Sciences, Inc. (KZR) is currently trading at $6.34 per share. The stock has moved +0.32% today.
What is the analyst price target for KZR?
The average analyst price target for KZR is $6.00, based on 1 analyst.
What sector is Kezar Life Sciences, Inc. in?
Kezar Life Sciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KZR's market cap?
Kezar Life Sciences, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does KZR pay dividends?
No, Kezar Life Sciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
BRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
XFOR
X4 Pharmaceuticals, Inc.
$3.60
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to KZR for comparison